Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 7Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Gastric Adenocarcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Liver Neoplasms 1Liver Diseases 1Leukemia, Myeloid, Acute 1Immune Checkpoint Inhibition 1ESCC 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Bites and Stings 1Advanced Hepatocellular Carcinoma 1

Interventions

camrelizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Immune Checkpoint Inhibition × camrelizumab × Clear all
NCT04507750 2020-09-21

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Qianfoshan Hospital

Phase NA Unknown
40 enrolled

Immune Checkpoint Inhibition

Data powered by HemOnc (CC BY 4.0) Colophon âš¡